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ercutaneous Revascularization for
table Coronary Artery Disease
emporal Trends and
mpact of Drug-Eluting Stents
e read with great interest the paper by Hilliard et al. (1) in JACC:
ardiovascular Interventions and congratulate the investigators on a
ery well-done and important analysis. Many of those who have
riticized the COURAGE (Clinical Outcomes Utilizing Revascu-
arization and Aggressive Drug Evaluation) study as not being
generalizable” to contemporary clinical practice (e.g., only 6% of
creened patients were randomized, percutaneous coronary inter-
ention [PCI] was substandard, too many patients enrolled from
eterans Affairs and Canada, very low rate of drug-eluting stent
sage, adherence to optimal medical therapy was not achievable in
he real world) should be reassured by the Mayo Clinic data. The
ayo data indicate that procedural success and technical profi-
iency continue to evolve and improve, in-hospital mortality and
arget vessel revascularization continue to decline, and results
chievable in the real world might even be better if more robust
ptimal medical therapy were more widely embraced and used.
The fact that the rates of death, death/myocardial infarction
MI), and revascularization in COURAGE at 4.6 years are
irtually identical to the rates reported from Mayo at 4 years
upports the concept suggested by the results of COURAGE that
hese late events (and need for subsequent revascularization) are
ot being driven by the stenoses that are initially “being fixed,” but
ather by new plaque ruptures in non-flow-limiting vessels. More-
ver, we note that the patient population undergoing PCI at Mayo
etween 1997 and 2003 was remarkably similar to patients enrolled
n COURAGE during the same time period. Table 4 of Hilliard
t al. (1) cites certain baseline characteristics of the Mayo popu-
ation that were higher risk than those of the COURAGE
opulation, but the investigators do not comment on the higher
ates of diabetes (32% vs. 24%), multivessel coronary artery disease
69% vs. 51%), and left anterior descending coronary artery disease
68% vs. 47%) in the COURAGE PCI cohort as compared with
he Mayo patients (2,3). Additionally, in their Table 1 (1), only
3% of patients in the Mayo Clinic cohort had a positive stress test
s the predominant indication for PCI, whereas in COURAGE,
ll patients had objective evidence of myocardial ischemia (2,3).
hus, when a more comprehensive list of characteristics is ana-
yzed it appears the Mayo and COURAGE PCI cohorts were
ndeed very comparable populations of North American stable
ngina patients. This is underscored further by the performance
nd outcomes of the PCI procedures that were very comparable in
oth studies and similar to contemporary practice in the National gardiovascular Data Registry (4). The difference in procedural
uccess noted in Table 4 (89% vs. 94%) of Hilliard et al. (1) is likely
ue to differing definitions (COURAGE excluded all periproce-
ural MIs whereas Mayo only excluded Q-wave MIs).
Based on these important observational data from a center
idely acknowledged for excellence in PCI and which serves to
alidate the quality of PCI in COURAGE, there can no longer be
ny debate that optimal medical therapy is the cornerstone of
anagement for all patients with stable coronary artery disease and
hould be the initial management strategy as concluded by the
OURAGE study. We also enthusiastically concur with Hilliard
t al. (1) that contemporary PCI is even safer and more efficacious
han in the bare-metal stent era and is an important complement
o optimal medical therapy for symptom relief in patients with
ngina that cannot be controlled by medications. Despite these
dvances, it is also noteworthy to emphasize that there has been no
hange in the unadjusted rates of mortality or the combined end
oint of death or MI in the drug-eluting stent era (2003 to 2006)
s compared with the bare-metal stent era (1997 to 2003) in the
ayo observational experience. Lastly, the hypothesis that coro-
ary revascularization improves prognosis in patients with severe
schemia is intriguing, but remains unproven, and must be evalu-
ted in a rigorously designed and performed randomized clinical
rial.
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e thank Drs. Sedlis and Boden for their interest in our article in
ACC: Cardiovascular Interventions (1). Although we agree that our
tudy suggests that “COURAGE-like” results are being achieved
n clinical practice, the analysis was not intended to investigate the
eneralizability of the trial (1,2). It is reasonable to propose that
